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Background: Certain psychotropics and a number of other medications used to treat medical 
conditions in psychiatric patients can increase the risk of prolonging the corrected QT (QTc) 
interval on the electrocardiogram, which puts patients at risk of life-threatening ventricular 
arrhythmias such as torsades de pointes. Pharmacists are often consulted about medications 
which are known to prolong the QTc interval. Although this information is often accessible, 
advising how to identify, assess, manage, and refer psychiatric patients at risk for drug-induced 
QTc prolongation is more challenging.
Objectives: The objective of this project was first to review the literature, which describes 
guidelines and recommendations for the assessment and management of drug-induced QTc 
prolongation, and then to design an algorithm to be used by pharmacists working closely with 
mental health professionals or who provide care to psychiatric patients.
Methods: A review of the literature was undertaken. Predefined keywords were used to perform 
the database search in MEDLINE, EMBASE, and International Pharmaceutical Abstracts to 
identify reviews, reports and guidelines on the assessment, prevention and monitoring of drug-
induced QTc prolongation with an emphasis on psychotropic medications and management in 
the psychiatric population.
Results: The electronic database search retrieved 637 relevant citations. These were initially 
screened by title and all duplicates were removed. The abstracts were then reviewed for 
relevancy based on the inclusion/exclusion criteria. Additional citations were retrieved from 
the bibliography of the articles identified in the initial search. A total of 79 articles describing 
QTc prolongation in the psychiatric population were thoroughly examined, but only 31 articles 
were selected to guide the development of the algorithm.
Conclusion: The literature-based algorithm developed provides a stepped-based approach 
for the assessment, monitoring, and management of drug-induced QTc prolongation in the 
psychiatric population. The algorithm may assist mental health clinicians in the decision-making 
process when psychiatric patients are prescribed medications known to increase the QTc interval.
Keywords: drug-induced arrhythmias, QT interval, torsades de pointes, guidelines, protocol, 
algorithm, mental, patients
Background
Prolongation of the QT interval is a concern for all clinicians as it can lead to fatal con-
sequences, such as sudden cardiac death (SCD).1 Among psychiatric patients, SCD is 
one of the major causes of premature mortality.2–5 Psychotropic medications have been 
implicated in the increased risk of SCD among psychiatric patients, primarily in view of 
their potential for prolonging the QT interval.3–6 Although relatively rare, prolongation 
Correspondence: M Zolezzi
Division of Clinical Pharmacy and 
Practice, College of Pharmacy, Qatar 
University, PO Box 2713, Doha, Qatar
Tel +974 4403 5623
email mzolezzi@qu.edu.qa 
Journal name: Neuropsychiatric Disease and Treatment
Article Designation: Review
Year: 2019
Volume: 15
Running head verso: Zolezzi and Cheung
Running head recto: Algorithm to assess drug-induced QTc prolongation
DOI: 186474
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
17
8.
15
2.
91
.1
7 
on
 2
5-
Ju
n-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2019:15submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
106
Zolezzi and Cheung
of the QT interval can be followed by a life-threatening 
polymorphic ventricular tachyarrhythmia called torsades de 
pointes (TdP).7,8 The mortality risk associated with TdP is 
high, estimated to be approximately 10%.8
TdP is commonly associated with hereditary or acquired 
forms of prolonged QT interval (also known as long QT syn-
drome [LQTS]).1 Mutations of the human hERG protein ion 
channels (potassium, calcium, and sodium), which contribute 
to the electrical activity of the heart, result in congenital 
LQTS (cLQTS).9 Acquired LQTS is almost always due 
to blockage or inhibition of the inward potassium rectifier 
(IKr) channel, which is critical in the phase 3 repolarization 
of the cardiac action potential.10 As with cLQTS, most cases 
of drug-induced long QT and TdP result from an action of 
the drugs on the ion channel proteins encoded by the hERG 
gene that is responsible for the IKr repolarizing current.11 
A recent study by Itoh et al reported that up to 28% of 
patients with drug-induced QT prolongation carry mutations 
causing the LQTS.12 The concept of repolarization reserve 
has been employed to account for individual differences in 
the susceptibility to develop TdP with drugs or conditions 
known to affect the heart’s potassium currents.11
The potential risk of TdP raises concerns among health 
care providers when prescribing medications known to inhibit 
hERG IKr channel, particularly in patients who may be 
predisposed.13 In addition, various psychotropic drugs have 
also been shown to inhibit inward ionic currents mediated by 
sodium and calcium.14,15 Besides psychotropic medications, 
other medications commonly used by psychiatric patients 
have also been implicated in prolonging the QT interval such 
as antiarrhythmic medications, antibiotics, antifungals, and 
antiemetic medications, some of which were removed from 
the market due to associated TdP.13
Studies have demonstrated that clinicians are often unable 
to identify TdP risk factors or medications that can prolong the 
QT interval.16,17 Fongemie et al reported discordance among 
cardiologists in the decision-making process when cor-
rected QT (QTc)-prolonging medications were to be used.17 
Furthermore, in daily practice, because of an ever-increasing 
number of medications available and other nondrug 
factors that must be accounted for during a risk assessment, 
clinicians may face difficulties on how to assess, man-
age, monitor and refer patients at risk of QTc prolongation.
Pharmacists are often consulted about medications that 
are known to prolong the QTc interval. To be meaningful, 
advice provided should extend beyond simple information 
about the potential for QT interval prolongation with a 
particular medication. However, this information may be 
more challenging for pharmacists to retrieve and difficult to 
interpret, particularly when caring for mental health patients 
who often have complex treatment regimens and who are 
often on poly-pharmacy. As such, the purpose of this paper 
was to summarize the literature describing guidelines and 
recommendations for the assessment and management of 
drug-induced QTc prolongation in psychiatric patients, and 
to develop an algorithm to guide all clinicians in the decision-
making process when psychiatric patients are prescribed 
medications with the potential of prolonging the QTc interval.
Methods
A literature search was conducted to identify pertinent pub-
lished literature. Three databases were searched: MEDLINE 
(Ovid), from 1946 to November 2017, EMBASE, from 
1974 to November 2017, and International Pharmaceutical 
Abstracts, from 1970 to November 2017. The following 
search strategy was used to identify relevant literature: 
(“guideline”[All Fields] OR “guidelines as topic”[MeSH 
Terms] OR “guidelines”[All Fields]) AND (“organization and 
administration”[MeSH Terms] OR (“organization”[All Fields] 
AND “administration”[All Fields]) OR “organization and 
administration”[All Fields] OR “management”[All Fields] OR 
“disease management”[MeSH Terms] OR (“disease”[All Fields] 
AND “management”[All Fields]) OR “disease management”[All 
Fields]) AND QTc[All Fields] AND interval[All Fields] 
AND prolongation[All Fields] AND (“patients”[MeSH Terms] 
OR “patients”[All Fields]) AND (“mental disorders”[MeSH 
Terms] OR (“mental”[All Fields] AND “disorders”[All Fields]) 
OR “mental disorders”[All Fields] OR (“mental”[All Fields] 
AND “illness”[All Fields]) OR “mental illness”[All Fields]) 
AND (“psychiatry”[MeSH Terms] OR “psychiatry”[All Fields] 
OR “psychiatric”[All Fields]) AND (“pharmaceutical 
preparations”[MeSH Terms] OR (“pharmaceutical”[All 
Fields] AND “preparations”[All Fields]) OR “pharmaceutical 
preparations”[All Fields] OR “medications”[All Fields]).
The initial screening consisted of reviewing the relevance 
of the article titles and then reviewing the abstracts of 
the articles that passed the initial title screening. Articles 
describing individual studies or systematic reviews discuss-
ing assessment, risk stratification, monitoring, and preven-
tion of QTc prolongation in the psychiatric population 
were included. Additional citations were retrieved from the 
bibliography of the articles identified in the initial search. 
Articles written in languages other than English, for which 
full-text articles could not be obtained or published before 
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Table 1 Articles reviewing QTc prolongation assessment and risk stratification among psychiatric patients
Author, year 
of publication
Summary of findings
Ojero-Senard 
et al, 201718
Notifications from a pharmacovigilance database were collected for patients on SRIs with QTc prolongation. QTc prolongation 
was only associated with citalopram and escitalopram and was noted as not being a side effect of SRis.
Barbui et al, 
201619
This cross-sectional survey showed that antipsychotic poly-pharmacy and antipsychotic dosing were associated with QTc 
interval prolongation.
Danielsson 
et al, 201620
This matched case-control register study showed that the CredibleMeds® system of TdP classification risk predicted drug-
related risk for mortality in the elderly.
Nose et al, 
201621
This cross-sectional study was conducted at several psychiatric centers to measure the frequency of QTc prolongation and 
associated risk factors. Risk factors that were associated with QTc prolongation included female sex, age, heart rate, alcohol 
and/or substance abuse, cardiovascular disease, cardiovascular drug treatment, drug overdose, and polypharmacy. Data support 
current guidelines that recommend avoiding the concurrent use of two or more antipsychotics and the link between citalopram 
and QTc prolongation, which necessitates routine eCG monitoring. 
Schächtele et al, 
201622
Hospital discharge prescriptions in a geriatric cohort were assessed for presence of QT-prolonging medications. A considerable 
proportion of QTc-prolonging medications with higher risk (as per CredibleMeds®) could only be detected by using more than 
one classification system. Adaptation of international classifications can improve identification of patients at risk.
Poncet et al, 
201523
An analytical model estimating the cost effectiveness of routine eCG screening to identify QTc prolongation in psychiatric hospitals 
revealed that performing systematic eCG at admission helped reduce the number of sudden cardiac deaths in a cost-effective fashion.
Rabkin, 201524 This literature review suggests that the association of increasing age and female sex with greater QT intervals necessitates 
awareness of the QTc prior to use of psychotropics and to measure QTc after initiation of therapy.
Takeuchi et al, 
201525
This systematic literature review claims that current evidence does not confirm that antipsychotic poly-pharmacy prolongs QTc, 
though poly-pharmacy with high-risk QTc-prolonging medications may increase the risk. Authors advise clinicians to remain 
conservative in prescribing antipsychotic poly-pharmacy considering that the clinical benefit of antipsychotic poly-pharmacy is lacking.
Shah et al, 
201426
Authors conclude that eCG monitoring when starting an antipsychotic in the absence of cardiovascular risk factors is not 
necessary. eCG monitoring is recommended if a patient has cardiovascular risk factors, if the antipsychotic is high-risk for TdP 
or sudden death, or if a patient has overdosed on an antipsychotic.
Girardin et al, 
201327
This cross-sectional study measured the prevalence of drug-induced QT prolongation as well as associated risk factors in 
patients admitted to a psychiatric hospital. QTc prolongation and arrhythmia occurrence increase when specific psychotropic 
drugs are started in patients with hypokalemia, abnormal T-wave morphology, HCv infection, and Hiv infection.
Krantz et al, 
201328
This study suggests that an eCG-based intervention in methadone maintenance can decrease the QTc interval in high-risk 
patients and that clinical characteristics alone are inadequate to identify patients who need eCG monitoring.
Tran and 
Dishman, 201229
Authors provide a review of citalopram-induced QTc prolongation and how to manage patients at risk, particularly those at high 
citalopram doses (eg. $40 mg in patients older than 60 years, or $20 mg in patients younger than 60 years).
wenzel-Seifert 
et al, 201130
The risk of QTc prolongation and TdP associated with common antipsychotics is reviewed. in addition, patients’ risk factors for 
QTc prolongation and TdP are reviewed, including age over 65 years, pre-existing cardiovascular disease, bradycardia, female sex, 
hypokalemia, hypomagnesemia, supratherapeutic/toxic serum concentration, or simultaneous administration of other drugs that 
delay repolarization or interfere with drug metabolism.
Yang et al, 
201131
Results of this cross-sectional naturalistic study among hospitalized patients with schizophrenia on long-term antipsychotics, 
revealed QTc prolongation was higher in women than in men. it was also found that clozapine led to more profound QTc 
prolongation than atypical antipsychotics and risperidone. Predictors of QTc prolongation identified included comorbid 
cardiovascular disease, antipsychotic types, sex, and age.
Abbreviations: eCG, electrocardiogram; FDA, US Food and Drug Administration; HCv, hepatitis C virus; QTc, corrected QT; SRis, serotonin reuptake inhibitors; TdP, 
torsades de pointes.
2010, were excluded. This timeline restriction ensured that 
only the most updated research findings were used in guiding 
the development of the algorithm.
Results
The electronic database search retrieved 637 relevant cita-
tions. These were initially screened by title and all dupli-
cates were removed. A total of 79 articles describing QTc 
prolongation in the psychiatric population were thoroughly 
examined, but only 31 articles were selected to guide the 
development of the algorithm. Based on the inclusion/
exclusion criteria described previously, the articles were 
grouped into the following categories:
1. Articles describing individual studies discussing risk 
factor assessment, risk stratification, and/or monitoring 
of the QTc interval in the psychiatric population. 
A total of 14 articles were included, a summary of the 
findings of these studies is presented in Table 1.18–31
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Table 2 Articles describing guidelines and protocols for assessing, monitoring, preventing or managing drug-induced QTc prolongation 
in the psychiatric population
Author, year of 
publication
Summary of findings
wahidi et al, 201632 Two case reports of TdP in patients on parenteral antipsychotics were reviewed and authors proposed practice guidelines 
for dosing parenteral antipsychotics in order to avoid TdP during the control of agitation at psychiatric hospitals.
Chou et al, 201433 This guideline, based on a systematic review of methadone safety, provides recommendations developed by a 
multidisciplinary expert panel. Safe use of methadone requires clinical skills and knowledge on use of methadone to mitigate 
potential risks, including serious risks related to risk of overdose and cardiac arrhythmias.
Fanoe et al, 201434 in this review, data from various authorities on the risk of arrhythmia associated with psychotropic medications were 
categorized into three risk categories. A clinical algorithm to reduce the risk of fatal arrhythmia in patients treated with 
psychotropics is proposed. The algorithm integrates the risk categories and risk factors and suggests follow-up parameters 
and timelines.
Pacciardi et al, 
201335
Authors summarized evidence-based safety considerations during the treatment of acute agitation with intramuscular 
antipsychotic medications in psychiatric patients.
De Heart et al, 
201136
This review evaluated the quality and content of various screening guidelines published between 2000 and 2010 for 
cardiovascular risk in schizophrenia.
Martin et al, 201137 A multidisciplinary expert panel concluded that treatment programs should have a cardiac risk management plan 
incorporating clinical assessment, ECG assessment, risk stratification, and prevention of drug interactions and should strongly 
consider risk minimization strategies that are patient-specific (eg, patient monitoring, ECG, adjusting methadone dosing).
Nielsen et al, 
201138
This article reviewed the mechanisms of QTc prolongation and the risk with antipsychotics, along with several clinical 
recommendations.
Fishman et al, 
201039
Six broad recommendations based on evidence were developed by a working group of experts jointly convened by the 
National Heart, Lung and Blood institute and the Heart Rhythm Society to address and recommend research directions and 
strategies in prediction and prevention of sudden cardiac death.
Modesto-Lowe 
et al, 201040
Retrospective analyses found that patients who develop TdP often have multiple risk factors, including high methadone doses, 
use of other medications that cause QTc prolongation, and electrolyte abnormalities. As such, guidelines are presented for 
initiating methadone in opioid treatment and pain populations.
Abbreviations: eCG, electrocardiogram; TdP, torsades de pointes;  QTc, corrected QT.
2. Articles describing guidelines or protocols for preventing, 
monitoring or managing drug-induced QTc prolongation 
in the psychiatric population. A total of nine articles 
were included and a summary of the recommendations 
provided in these articles is presented in Table 2.32–40
3. Review articles about drug-induced QTc prolongation risk 
stratification in nonpsychiatric patients from which relevant 
recommendations were extrapolated to support develop-
ment of the algorithm. A total of eight review articles were 
included and these are summarized in Table 3.41–48
As illustrated in Figure 1, the literature-based algorithm 
developed provides a stepped-based approach for the 
assessment, management, and monitoring of psychotropic-
induced QTc prolongation in the psychiatric population. 
The algorithm includes a set of questions which facilitate the 
decision-making process and the evidence that supports the 
decision points.
Step 1: assessing the medication risk
The starting point is assessing the medication prescribed. 
When prescribing a psychotropic agent or any other 
medication for psychiatric patients who are taking 
psychotropic medications, particularly antipsychotics or 
antidepressants, the first step consists of assessing the pre-
scribed drug.18,20,22,29,30,34,38,42,47 The most comprehensive and 
easily accessible reference source for medications known 
or suspected to cause QT prolongation is CredibleMeds® 
accessible through the world wide web (WWW) at 
www.crediblemeds.org.49 This website is maintained by 
AZCERT (The Arizona Center for Education and Research 
on Therapeutics), a nonprofit organization, that uses a 
rigorous, systematic risk stratification process to determine 
a medication’s likelihood to cause QT prolongation or TdP.50 
The evidence on this website is monitored closely and updated 
frequently. Clinicians can register and subscribe to updates 
from the website. CredibleMeds® is also available through a 
mobile application which can easily be accessed by clinicians 
on their cell phones, iPads or other pocket devices.
CredibleMeds® classifies medications into four categories: 
Category 1 Drugs, those with known risk of TdP; these drugs 
prolong the QT interval and have an associated known risk 
of TdP even when taken as recommended. Category 2 Drugs, 
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Table 3 Review articles about QTc prolongation (not specifically in the psychiatric population) included in the development of the 
algorithm
Author, year of 
publication
Summary of findings
institute for Safe 
Medication Practices 
Canada®, 201741
institute for Safe Medication Practices Canada® (iSMP Canada) developed an evidence-based tool to help pharmacists 
evaluate and communicate QT prolongation risk. 
Tisdale, 201642 This article described the important role that pharmacists play in minimizing the risk of drug-induced QTc prolongation 
and TdP. This article reviews clinical assessment of risk of QTc prolongation (via the QTc interval prolongation risk 
score), drug interactions that increase risk of TdP, and dose reductions of renally eliminated QTc-prolonging drugs in 
patients with kidney disease.
Jardin et al, 201443 This retrospective analysis assessed risk factors for TdP in hospitalized patients receiving $1 QTc-prolonging 
medication. The following risk factors were associated with significant QTc prolongation: female sex, LVEF ,40%, and 
cardiac arrest.
Tisdale et al, 201444 The authors described a computerized clinical decision support system developed to alert pharmacists to drugs that 
lead to QTc prolongation among patients admitted to coronary care units at moderate/high risk of QTc prolongation. 
when alerted, pharmacists were to contact prescribers to decrease risk of TdP. The use of this system resulted in a 
significant reduction in the prescribing of QT-prolonging medications.
Haugaa et al, 201345 This institution-wide QT alert system was used to alert prescribers to patients with a QTc of over 500 ms. Mortality 
was increased among those with increasing pro-QTc scores, which was an independent predictor of mortality.
Tisdale et al, 201346 A prospective observational study was conducted on 900 patients admitted to cardiac care units to develop and validate 
a risk scoring system that could predict patients at highest risk of developing QTc prolongation. The tool is used to 
distinguish whether patients are at low, medium, or high risk of QTc interval prolongation based on a score that is 
obtained by number of risk factors and their weighting.
Nachimuthu et al, 201247 This article reviewed the mechanism of drug-induced QT prolongation, risk factors for TdP, culprit drugs, prevention, 
and monitoring of prolonged drug-induced QT prolongation and treatment strategies.
Drew et al, 201048 This scientific statement reviewed the risk, ECG monitoring, and management of drug-induced LQTS. Authors reviewed 
signs of arrhythmia, mechanisms of acquired LQTS, drug combinations known to cause TdP, risk factors/exacerbating 
conditions, methods to monitor QT intervals, and management of QT prolongation and TdP.
Abbreviations: LQTS, long QT syndrome; LveF, left ventricular ejection fraction; QTc, corrected QT; TdP, torsades de pointes.
those with possible risk of TdP; these drugs have the potential 
to cause QT prolongation, but there is a lack of evidence 
for TdP risk. Category 3 Drugs, those with conditional risk 
of TdP; these drugs are associated with TdP but only under 
certain circumstances or in patients with certain “at-risk” 
characteristics. Category 4 Drugs, those to be avoided in 
patients with cLQTS.50 Currently, 57 medications are on the 
list of drugs known to cause TdP. Another 92 are on the list 
with “possible risk of TdP” and 43 are on the “conditional 
risk” list. Two hundred and twenty-four medications are on 
the list of “drugs to avoid” for patients with cLQTS.50
Step 2: assessing the prescribed 
medication dose, route of administration, 
and drug interactions
For the majority of QT-prolonging drugs, risk increases as a func-
tion of dose and plasma drug concentration.19,21,22,25,30,37,38,42,43,48 
It has been recognized that drug plasma concentrations could 
be affected by multiple factors including dose, formulation 
form, route, frequency, administration time, drug–drug 
interaction, food–drug interaction, genetics, sex, age, body 
weight, pregnancy, circadian rhythms, comorbidities, 
pathophysiology status, and smoking.51 As such, depending 
on the type of medication used, weight-based dosing should 
be considered particularly for populations who are more 
vulnerable to increased plasma levels if not dosed according 
to weight (eg, elderly).52
The route of administration can also have an effect on 
the QT-prolonging extent of a drug, as medications adminis-
tered intravenously tend to have higher potential of causing 
QT prolongation as opposed to oral administration.30,32,35 
Intravenous administration can be associated with higher 
drug concentrations and thus greater cardiac exposure 
than corresponding oral dosing.47 Finally, rapid infusion 
of a QT-prolonging medication is also a risk factor for QT 
prolongation.30,42,43 Conditions that lead to elevated plasma 
concentrations of QTc interval-prolonging drugs increase the 
risk of drug-induced TdP, including pharmacokinetic drug 
interactions and inadequate dose adjustment of renally elimi-
nated QTc interval-prolonging drugs in patients with acute 
kidney injury or chronic kidney disease.42,47 In addition, com-
petitive protein binding can potentially cause increased serum 
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Figure 1 A literature-based algorithm for the assessment, management and monitoring of drug-induced QTc prolongation.
Notes: *As per CredibleMeds®. aAs per Tildale et al.46
Abbreviations: cLQTS, congenital long QT syndrome; eCG, electrocardiogram; eF, ejection fraction; QTc, corrected QT; TdP, torsades de pointes.
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levels of medications that prolong QTc when combined with 
seemingly benign medications that are highly protein bound, 
such as acetylsalicylic acid and sodium valproate, and some 
herbal preparations.30 A comprehensive and easily accessed 
reference source in the WWW for pharmacokinetic inter-
actions is available from Medscape® at https://reference.
medscape.com/drug-interactionchecker. CredibleMeds® 
also lists medication combinations which should be used 
with caution by identifying medications that could cause 
additive pharmacodynamic interactions with psychotropic 
medications that prolong QTc.49,50
Step 3: assessing the patient’s risk of QTc 
prolongation and TdP
Electrolyte abnormalities, particularly hypokalemia, hypo-
magnesemia, and hypocalcemia, are known risk factors for QT 
prolongation.27,30,34,40–43,47,48 Drug-induced QTc prolongation 
also occurs more commonly in females than in males, and the 
effects are more pronounced in older patients above the age 
of 65 years.20,22,23,30,31,34,42,43,47 Patients with an underlying heart 
disease including cLQTS, myocardial ischemia, cardiomyo-
pathy, cardiac arrhythmias, bradycardia, or congestive heart 
failure are also predisposed to QT prolongation in comparison 
to healthy counterparts.22,26,27,30,31,34,37,38,42,43,48 Because many 
hospitalized patients often have other risk factors for a pro-
arrhythmic response, such as older age with an underlying 
heart disease who may also have renal or hepatic dysfunction, 
electrolyte abnormalities, or bradycardia and to whom drugs 
may be administered rapidly via the intravenous route, admin-
istration of a QT-prolonging drug to a hospitalized popula-
tion may be more likely to cause TdP than administration of 
the same drug to an outpatient population.32,35,43,48,49
There are three manual stratification tools published in 
the literature that clinicians can use to determine individual 
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QTc-prolongation risk.45,46,49 Of these, only the one devel-
oped by Tisdale et al has been validated.46 This risk scoring 
tool allows quantification of a patient’s risk based on the 
presence or absence of a total of ten possible risk factors, 
with a maximum possible score of 21. This scoring system 
classifies patients as low, medium or highrisk (QTc score 7, 
8–10 or $11, respectively). In a subsequent study, the same 
authors were able to demonstrate that incorporating this 
validated risk scoring tool into a decision support tool sys-
tem influenced the prescribing of QT-prolonging drugs and 
reduced the risk of QTc interval prolongation in hospitalized 
patients with TdP risk factors.44
Step 4: determining the need for measuring 
the QT interval
Although monitoring of the QT interval by electrocardiogram 
(ECG) prior to treatment with QT-prolonging drugs is often 
recommended by the drug manufacturers, indications for 
obtaining a baseline ECG and/or routine ECG monitoring are 
mixed in the literature.23,26,28,34,36,47,53 Although it may be easier 
in an inpatient setting, a wearable remote monitoring system 
has been recommended for the identification of subjects 
with cLQTS or at risk for drug-induced LQTS in outpatient 
settings.54 De Hert et al conducted a systematic review of 
various guidelines for cardiovascular risk with antipsychotic 
medications and found that 50% of guidelines support ECG 
monitoring for psychotropic agents with the potential to 
prolong the QTc interval.36 Based on the risk assessment, 
patients with a QTc risk score of 7 when using the validated 
risk scoring tool developed by Tisdale et al, or those taking 
high-risk drug combinations, should have an ECG when the 
plasma concentration of a new QT-prolonging agent reaches 
steady state (ie, five half-lives following initiation).42
Magnesium and potassium levels should also be checked 
with ECG.46 When following-up on an ECG done at steady 
state, drug-induced QT prolongations of ,25 ms are con-
sidered insignificant by some clinicians, though the increase 
of 60 ms or QTc intervals of over 500 ms are a cause for 
concern and more frequent monitoring or the cessation of 
therapy is recommended in such cases.24,42
Other situations that warrant ECG monitoring include 
overdoses of medication with QT-prolonging potential, when 
more than one QTc-prolonging medication is prescribed in 
combination, when a patient experiences cardiovascular 
symptoms, in patients with cardiovascular disease, and in 
cases of electrolyte derangements.26,34,42 Some medications 
have specific ECG recommendations available. For instance, 
the Center for Substance Abuse and Mental Health Services 
Administration (CSAT), an independent multidisciplinary 
expert panel, developed guidelines on cardiac safety 
recommendations for methadone prescribers.28 The guide-
lines recommend a pretreatment ECG for all patients prior 
to initiating methadone, a follow-up ECG within 30 days, 
and then annually thereafter or sooner if there is a change in 
dosage. Increased monitoring is recommended if a patient has 
a QT interval over 450 ms. If the QT interval exceeds 500 ms, 
discontinuation of methadone should be considered.
Step 5: recommending strategies to  
minimize the likelihood of drug-
induced TdP
If cardiac risks are identified, the cardiac risk factors should 
be optimized and/or a drug with a more favorable risk profile 
should be chosen if possible. In case of structural heart 
disease, QT prolongation, electrolyte disturbances, or cardiac 
symptoms, referral to a cardiologist should be considered.34 
Re-evaluation of the ECG and symptoms should take place 
within 1 or 2 weeks or at steady state (five times the drug 
half-life) after initiation of treatment with class 1 drugs or 
with class 3/4 drugs if used in combination.34 Similarly, 
a significant increase in dose of these drugs necessitates 
re-evaluating symptoms and a new ECG.34
A QTc interval above 500 ms or an increment above 
60 ms when compared with baseline is generally associated 
with a definite increased risk of TdP and should in most 
cases lead to discontinuation of the drug.34,47 It is suggested 
to consult a cardiologist if the QTc stays prolonged after 
discontinuing medication, if cardiovascular symptoms are 
present, or in case of pre-existing cardiac disease or when 
a strong family history exists. Several other QTc scenarios 
occurring during treatment also merit specialist consultation, 
such as in pediatric patients, in the elderly, and in frail 
(ie, hospitalized) individuals.48
Discussion
The literature review undertaken provides a comprehensive 
list of studies, reports, and guidelines for the assessment, 
monitoring, and management of drug-induced QTc prolon-
gation in the psychiatric population. In order to facilitate the 
translation of evidence-based recommendations into practice, 
a stepped-care approach was used in the development of 
the algorithm to assist mental health clinicians in making 
decisions when medications known to increase the QTc 
interval are used.
In a similar algorithm developed by Fanoe et al, the risk 
of arrhythmia associated with various classes of psychotropic 
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medications was described.34 We believe that our algorithm 
adds value to the one developed by Fanoe et al as it provides 
a stepped-care approach with a set of clinical questions that 
are intended to help in rationalizing the decision-making 
process. Fanoe et al did not recommend the use of a specific 
QTc risk scoring tool, and rather suggested seeking a cardi-
ologist consultation when patients present with any positive 
risk factors for prolonged QTc. Our algorithm still supports 
cardiology consultation, especially in those whose risk score 
is .7 points. In 2002, the Cardiac Safety in Schizophrenia 
Group released a series of consensus statements on how to 
minimize the risks associated with significant QTc prolonga-
tion in people with schizophrenia.55 These, however, have not 
been updated since and consequently have no information on 
newer medications or on medications other than those used 
for the management of schizophrenia; thus, our algorithm is 
more inclusive of other psychiatric diagnoses and provides 
a more updated resource for clinicians.53
Common findings in the literature review which guided 
the development of this algorithm include the use of 
CredibleMeds® as an important evidence-based resource, 
as well as the importance of cardiac risk stratification in the 
assessment and management of drug-induced QTc prolonga-
tion. Studies have shown that prescribers do not routinely 
screen for cardiac risk factors in psychiatric patients.53,56,57 
In addition, because ECG monitoring may not be possible 
or readily accessible in both outpatient and inpatient set-
tings, or in all psychiatric facilities, the algorithm developed 
highlights the importance of assessing the associated risk 
factors as early as possible before making recommendations 
on the use of medications with QTc-prolonging risk, primar-
ily those listed as Category 1–3 by CredibleMeds® or those 
that are known inhibitors of the hERG IKr channel.11,49,53,56–58 
Current research initiatives, such as the Comprehensive 
in vitro Proarrhythmia Assay (CiPA), are developing and 
validating a model to test the proarrhythmic risk of drugs 
by assessing the effect of drugs on multiple ion channels 
and integrating ECG analysis in early phase I clinical trials 
to better predict proarrhythmic risk.59 If successful, CiPA 
will 1) create a pathway for drugs with hERG block/QT 
prolongation to advance without intensive ECG monitoring 
in phase III trials if they have low proarrhythmic risk and 
2) enable updating of drug labels to be more informative 
about proarrhythmic risk, not just QT prolongation.59
Despite the robustness of our literature review, the 
algorithm developed is not without limitations. The algorithm 
incorporates a tool to predict the risk of QTc prolongation 
that was developed by Tisdale et al and validated only in 
nonpsychiatric populations.42,44 Thus, it is uncertain how the 
risk scoring tool will perform in patients with psychiatric 
disorders who are known to be at higher risk of cardiac 
events regardless of the medications they are on.60 Future 
testing of this stepped-based algorithm with regard to its 
usefulness in guiding pharmacists and other clinicians in the 
decision-making process when medications are prescribed 
to mental health patients is necessary.
Conclusion
The algorithm developed provides a stepped approach for 
assessing and managing the risk of QTc prolongation when 
prescribing medications for patients with psychiatric disor-
ders. The stepped approach described may also be appropriate 
when assessing drug-induced QTc prolongation risk in indi-
viduals without psychiatric disorders. Further investigations 
dedicated to the validation of this stepped-based algorithm 
are required, including face validation and the feasibility for 
its routine use by clinicians, including an evaluation of the 
outcome of its use over time.
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